肺部肿瘤个体化立体定向消融放疗:iSABR 2期非随机对照试验
iSABR 2期多中心非随机对照试验于2011年11月15日至2018年12月5日在美国和日本的学术医疗中心入组217例患者,按肿瘤类型分3组,对最多4个肿瘤行每日一次SABR,剂量按肿瘤大小和位置个体化(外周0-10 cm³为25 Gy单次,中央>30 cm³为60 Gy/8次)。1年局部无复发率1组97%、2组94%、3组96%,5年局部无复发率三组为83%至93%,3-5级毒性发生率为5%(含1例5级毒性)。作者认为个体化SABR可最小化治疗剂量并与优异的局部控制相关,建议未来试验考虑使用个体化剂量。
要点
- 按肿瘤大小、位置和组织学特征个体化SABR剂量与分割,1年局部无复发率三组为94%至97%。
- 5年局部无复发率三组范围为83%至93%,中位随访33个月。
- 3-5级毒性发生率为5%,包括1例(1%)5级毒性。
核心结论
- 该非随机对照试验结果提示,用于治疗肺部肿瘤的个体化SABR(iSABR)可能允许最小化治疗剂量,并与优异的局部控制相关。
- 作者认为未来试验应考虑使用个体化剂量。
研究设计与样本
- iSABR为2期多中心非随机对照试验,于2011年11月15日至2018年12月5日在美国和日本的学术医疗中心入组参与者。
- 共217例唯一患者入组(部分多次入组),中位(IQR)年龄72(64-80)岁,129例(59%)男性,150例(69%)为当前或既往吸烟者。
- 共240个治疗疗程:1组79个、2组82个、3组79个;共治疗285个肿瘤(211个[74%]外周、74个[26%]中央)。
- 患者按肿瘤类型分3组:1组为初诊非小细胞肺癌(NSCLC)AJCC第7版T1-3N0M0;2组为有既往NSCLC史或多发NSCLC的新原发T1-3N0M0 NSCLC;3组为NSCLC或其他实体瘤的肺转移。
- 最多4个肿瘤接受每日一次SABR,剂量从外周0-10 cm³肿瘤的25 Gy单次至中央>30 cm³肿瘤的60 Gy/8次。
主要发现
- 最常见剂量为25 Gy单次(158个肿瘤)。
- 中位(范围)随访33(2-109)个月,中位总生存为59(95% CI,49-82)个月。
- 1年局部无复发率:1组97%(90% CI,91%-99%),2组94%(90% CI,87%-97%),3组96%(90% CI,89%-98%)。
- 5年局部无复发率三组范围为83%至93%。
- 3-5级毒性反应患者比例为5%,包括1例(1%)5级毒性反应。
关键数值与推荐
- 剂量范围:外周0-10 cm³肿瘤为25 Gy单次,中央>30 cm³肿瘤为60 Gy/8次。
- 1年局部无复发率:1组97%(90% CI,91%-99%)、2组94%(90% CI,87%-97%)、3组96%(90% CI,89%-98%)。
- 5年局部无复发率三组为83%至93%。
- 3-5级毒性发生率为5%,含1例(1%)5级毒性。
临床怎么用
- 作者认为个体化SABR可能允许最小化治疗剂量并与优异的局部控制相关。
- 作者建议未来试验考虑使用个体化剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small tumors up to 10 cm3 in volume can be well controlled with a biologically effective dose less than 100 Gy. OBJECTIVE: To assess whether individualizing lung SABR dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial (the iSABR trial, so named for individualized SABR) was a phase 2 multicenter trial enrolling participants from November 15, 2011, to December 5, 2018, at academic medical centers in the US and Japan. Data were analyzed from December 9, 2020, to May 10, 2023. Patients were enrolled in 3 groups according to cancer type: initial diagnosis of non-small cell lung cancer (NSCLC) with an American Joint Committee on Cancer 7th edition T1-3N0M0 tumor (group 1), a T1-3N0M0 new primary NSCLC with a history of prior NSCLC or multiple NSCLCs (group 2), or lung metastases from NSCLC or another solid tumor (group 3). INTERVENTION: Up to 4 tumors were treated with once-daily SABR. The dose ranged from 25 Gy in 1 fraction for peripheral tumors with a volume of 0 to 10 cm3 to 60 Gy in 8 fractions for central tumors with a volume greater than 30 cm3. MAIN OUTCOME: Per-group freedom from local recurrence (same-lobe recurrence) at 1 year, with censoring at time of distant recurrence, death, or loss to follow-up. RESULTS: In total, 217 unique patients (median [IQR] age, 72 [64-80] years; 129 [59%] male; 150 [69%] current or former smokers) were enrolled (some multiple times). There were 240 treatment courses: 79 in group 1, 82 in group 2, and 79 in group 3. A total of 285 tumors (211 [74%] peripheral and 74 [26%] central) were treated. The most common dose was 25 Gy in 1 fraction (158 tumors). The median (range) follow-up period was 33 (2-109) months, and the median overall survival was 59 (95% CI, 49-82) months. Freedom from local recurrence at 1 year was 97% (90% CI, 91%-99%) for group 1, 94% (90% CI, 87%-97%) for group 2, and 96% (90% CI, 89%-98%) for group 3. Freedom from local recurrence at 5 years ranged from 83% to 93% in the 3 groups. The proportion of patients with grade 3 to 5 toxic effects was low, at 5% (including a single patient [1%] with grade 5 toxic effects). CONCLUSIONS AND RELEVANCE: The results of this nonrandomized controlled trial suggest that individualized SABR (iSABR) used to treat lung tumors may allow minimization of treatment dose and is associated with excellent local control. Individualized dosing should be considered for use in future trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01463423.
引用
- Gensheimer MF, Gee H, Shirato H, et al. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023. PMID: 37707820. doi:10.1001/jamaoncol.2023.3495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。